NCT07524257 2026-04-13
ResQ1010-NSCLC: NAI + Chemoimmunotherapy vs Chemoimmunotherapy for First-Line Advanced/Metastatic NSCLC
ImmunityBio, Inc.
Phase 3 Not yet recruiting
Clinical Trials
9 trialsNCT07383116 2026-02-03
Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer
Shanghai Huaota Biopharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT07154368 2025-09-19
JYP0322 Versus Platinum Based Doublet Chemotherapy in ROS1 Positive Patients Previously Treated With ROS1-TKIs.
Guangzhou JOYO Pharma Co., Ltd
Phase 3 Not yet recruiting
NCT07109531 2025-08-07
ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy
Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT06970782 2025-05-21
KYLIN-3
Avistone Biotechnology Co., Ltd.
Phase 3 Not yet recruiting
NCT06704620 2024-12-16
Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 3 Not yet recruiting
NCT06380348 2024-04-23
JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations
Shanghai JMT-Bio Inc.
Phase 3 Not yet recruiting
NCT05990127 2023-08-14
A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer
Akeso
Phase 3 Not yet recruiting
NCT04772287 2021-02-26
Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008)
Shanghai Pulmonary Hospital, Shanghai, China
Phase 3 Not yet recruiting